N-acetylcysteine for Primary Sjögren's Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-30

Study Completion Date

2025-01-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

N-acetylcysteine (NAC) allows the elimination of reactive oxygen species (ROSs) and it has an anti-inflammatory effect. For this reason, NAC has been used and researched for treatment of several diseases, such as autoimmune diseases. In these diseases there are a process of oxidative stress due to chronic inflammation, which promotes an imbalance between ROSs levels and the cellular capacity to eliminate reactive intermediates and repair the resulting damage through antioxidants. The imbalance between the production of free radicals from oxygen and antioxidant species may also be involved in the pathogenesis of primary Sjögren's syndrome (pSS). In fact, increased levels of oxidative stress markers were detected in biopsy samples from minor salivary glands in these patients. Treatment of pSS is not well established and it is also not able to modify the evolution of the disease, being often only symptomatic. In addition, there is little data in the literature regarding the true efficacy of NAC in the treatment of pSS and the few existing studies have evaluated heterogeneous populations (including patients with other causes of sicca syndrome) and validated instruments to measure the symptom index and disease activity were not use in these previous studies. Thus, the present randomized double-blind clinical study aims to evaluate the efficacy of NAC in the control of sicca syndrome symptoms in a homogeneous population of patients with pSS (not only regarding the classification criteria, but also regarding the low rate of systemic disease activity at study inclusion) through tests widely accepted in the literature. Additionally, the investigators will study the possible role of NAC on oxidative stress in peripheral blood and saliva of these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

NCT01782235

Primary Sjögren's Syndrome (pSS)

COMPLETED PHASE2/PHASE3

Examining the Immunological Process of Autoimmune Patients

NCT02123147

Sjogren's Syndrome Autoimmune Diseases Dry Eyes +1 more

WITHDRAWN

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

NCT02422407

Healthy Sicca Syndrome Sjögren's Syndrome

COMPLETED

High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis

NCT00428883

Scleroderma, Diffuse

UNKNOWN PHASE2/PHASE3

Interstitial Lung Diseases in Primary Sjogren's Syndrome

NCT04978883

Sjogren's Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design: This is a prospective, randomized, double-blind controlled study of N-acetylcysteine (600 mg orally every 12 hours in the form of syrup) lasting 12 weeks for the treatment of sicca syndrome symptoms due to pSS.

Patients: Sixty adult female patients (aged \>=18 years), with a well-established diagnosis of pSS (2016 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) and/or 2002 American-European Consensus classification criteria) and follow-up regularly at the Sjögren Syndrome Outpatient Clinic of the Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP).

Sample size: There is only a controlled study of NAC for treatment of SS, which included a heterogeneous population with a total of 26 patients and who observed superiority to placebo in the sicca symptoms control. Based on this study, the investigators will work with a convenience sample of 60 patients.

Clinical evaluation: It will be carried out at study inclusion, 4 weeks and 12 weeks through clinical instruments widely accepted in the literature.

Laboratorial evaluation: ROs will also be assessed throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sjögren Syndrome Sicca Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blind controlled study of N-acetylcysteine for treatment of dryness symptoms due to primary Sjogren's syndrome

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Blinding of identical bottles of N-acetylcysteine and placebo syrup

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

N-acetylcysteine syrup

Thirty pSS patients

Group Type ACTIVE_COMPARATOR

N-acetylcysteine syrup

Intervention Type DRUG

N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months

Placebo syrup

Thirty pSS patients

Group Type PLACEBO_COMPARATOR

Placebo syrup

Intervention Type DRUG

Placebo syrup 15 mL twice a day for 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N-acetylcysteine syrup

N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months

Intervention Type DRUG

Placebo syrup

Placebo syrup 15 mL twice a day for 3 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

N-acetylcysteine Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Agreement to participate in the study according to signed informed consent.
* Filling the pSS classification criteria.
* Absence of other autoimmune associates systemic diseases.
* EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) \<= 5.
* Prednisone dose \< 20 mg/day at study inclusion.
* Without pilocarpine or cevimeline use at study inclusion.
* No use of N-acetylcysteine for at least 1 month before study inclusion.

Exclusion Criteria

* Diabetes, sarcoidosis, previous history of head and neck radiotherapy or iodine therapy, positive serologies for HIV, hepatitis B and C, graft versus host disease, IgG4 (immunoglobulin G4) related disease, and current use of antidepressants tricyclics.
* Current use of biological therapy.
* Current smoking.
* Alcoholism.
* Liver cirrhosis and chronic kidney disease.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No